Journal article

Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST)

John H Kempen, Mark L Van Natta, Michael M Altaweel, James P Dunn, Douglas A Jabs, Susan L Lightman, Jennifer E Thorne, Janet T Holbrook

American Journal of Ophthalmology | ELSEVIER SCIENCE INC | Published : 2015

Grants

Awarded by NATIONAL EYE INSTITUTE (BETHESDA, MARYLAND)


Funding Acknowledgements

THIS STUDY IS SUPPORTED BY NATIONAL EYE INSTITUTE (BETHESDA, MARYLAND) COLLABORATIVE Agreements U10EY014655 (Dr Jabs), U10EY014660 (Dr Holbrook), and U10EY014656 (Dr Altaweel). Bausch & Lomb (Rochester, New York) provided support to the study in the form of donation of fluocinolone implants for patients randomized to implant therapy who were uninsured or otherwise unable to pay for implants, or were located at a site where implants could not be purchased (eg, in the United Kingdom). Additional support was provided by Research to Prevent Blindness (New York, New York), the Paul and Evanina Mackall Foundation (New York, New York), and the Lois Pope Life Foundation (New York, New York). A representative of the National Eye Institute participated in the conduct of the study, including the study design and the collection, management, analysis, and interpretation of the data, as well as in the review and approval of this manuscript. Financial Disclosures: In the last 3 years, John H. Kempen has served as a consultant for AbbVie (North Chicago, Illinois), Alcon (Fort Worth, Texas), Allergan (Irvine, California), Can-Fite (Peta-Tikva, Israel), Clearside (Alpharetta, Georgia), Lux Biosciences (Jersey City, New Jersey), Roche (Basel, Switzerland), and Xoma.(Berkeley, California); Douglas A. Jabs is a consultant for Santen, Inc (Osaka, Japan) and serves on Data and Safety Monitoring Committee's for Novartis (Basel, Switzerland) and Applied Genetic Technologies Corporation (Alachua, Florida); Susan L. Lightman has served as a consultant and is a grantee from Allergan, GSK (London, United Kingdom), and Bayer (Leverkusen, Germany); and Jennifer E. Thorne is a consultant for AbbVie, Gilead Sciences (Foster City, California), and Xoma and receives research funding from Allergan. The following authors have no financial disclosures: Mark L. Van Natta, Michael M. Altaweel, James P. Dunn, and Janet T. Holbrook. All authors attest that they meet the current ICMJE criteria for authorship.